Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolios

Bond Yield Curve Inverts: 3 Defensive Stocks To Buy

Published 08/15/2019, 12:38 AM
Updated 07/09/2023, 06:31 AM
KMB
-
NG
-
PG
-
CPK
-
US30YT=X
-

The U.S. bond market has indicated what some people believe to be the biggest warning of an upcoming recession. The spread between the 2-year treasury yield and the 10-year yield inverted, with the 2-year yield climbing higher than the benchmark 10-year yield for the first time since 2007.

On top of that, the U.S. 30-year bond yield fell to a record low early Wednesday, dropping down to 2.105% for the first time ever. Bond yield drops were not exclusive to the U.S., yields across Europe fell with the German 10-year bund reaching a new low of -0.65%. Strategists believe that a yield curve must stay inverted for it to truly signal a recession. Therefore, current bond yields are cause for concern only if they remain inverted. An inverted bond yield curve has been a reliable indicator of economic contractions but it does not always precede a recession.

With some bond yields at all-time lows amid broader economic uncertainty, investors have turned toward defensive stocks. Let’s take a closer look at a few stocks that can perform well during global economic uncertainty.

Procter & Gamble (NYSE:PG) is part of the consumer staples industry that is often seen as a relatively defensive move during market unpredictability. PG is a Zacks Rank #2 (Buy) right now and its shares have climbed 27.7% in 2019, with the broader soaps and cosmetics market trailing close behind, up 20%.

PG had a solid Q4 2019, beating earnings and revenue estimates by 3.77% and 1.31%, respectively. Furthermore, both revenue and earnings grew Y/Y in Q4. Zacks Consensus estimates project PG’s growth to continue in Q1 2019 with earnings projected to climb 10.71% and revenue to pop 4.82% to $17.49 billion. Furthermore, estimate revisions have ticked favorably in the right direction for PG as the chart below shows.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Kimberly-Clark (NYSE:KMB) is another consumer staples stock that has had a strong year, with KMB stock up 22%. The company operates some of the most recognizable personal care brands such as: Huggies, Pull-Ups, Kleenex, and Scott. Kimberly-Clark continued its strong 2019 with a second-quarter earnings beat that saw its EPS jump 5% to $1.67 per share.

KMB also raised its full-year earnings outlook to $6.65-$6.80, up from management’s previous estimate of $6.50-$6.70. Consensus estimates calls for KMB to sustain this bottom-line growth in Q3 with a jump of 4.68% to $1.79 on the back of 2.02% higher sales that would see it reach to $4.67 billion. Positive top and bottom-line growth is projected through 2020 and Kimberly-Clark sports a Zacks Rank #2 (Buy).

Chesapeake Utilities (NYSE:CPK) is a utility company engaged in natural gas distribution and transmission. Utilities are generally more stable stocks as the demand for electricity and gas often remains constant despite broader economic conditions. Utilities companies are also non-cyclical and don’t often move with larger market trends. CPK has a beta of 0.24 and pays out a quarterly dividend of $1.62, with a yield of 1.75% at the moment.

Chesapeake’s quarterly dividend paired with its low volatility can provide investors with a secure defensive investment. Consensus estimates also forecast CPK’s bottom-line to spike 5.88%, while sales surge 21.33% to $170.2 million in Q3. Looking ahead to the company’s full fiscal year outlook, estimates call for earnings to pop 12.39% to $3.72 and revenue to grow 6.95% to $767.37 million. Like its defensive peers, CPK is Zacks Rank #2 (Buy) at the moment.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>



Chesapeake Utilities Corporation (CPK): Free Stock Analysis Report

Kimberly-Clark Corporation (KMB): Free Stock Analysis Report

Procter & Gamble Company (The) (PG): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.